Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Mar;25(2):187-93.
doi: 10.3109/14397595.2014.951144. Epub 2014 Sep 11.

Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks

Hiroto Tsuboi  1 , Isao Matsumoto, Shinya Hagiwara, Tomoya Hirota, Hiroyuki Takahashi, Hiroshi Ebe, Masahiro Yokosawa, Chihiro Hagiya, Hiromitsu Asashima, Chinatsu Takai, Haruka Miki, Naoto Umeda, Yuya Kondo, Hiroshi Ogishima, Takeshi Suzuki, Shintaro Hirata, Kazuyoshi Saito, Yoshiya Tanaka, Yoshiro Horai, Hideki Nakamura, Atsushi Kawakami, Takayuki Sumida
Affiliations
Observational Study

Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks

Hiroto Tsuboi et al. Mod Rheumatol. 2015 Mar.

Abstract

Abstract Objective. To assess the efficacy and safety of abatacept for secondary Sjögren's syndrome (SS) associated with rheumatoid arthritis (RA). Methods. The primary endpoint of this 1-year, open-labeled, prospective, observational multicenter study of RA-associated secondary SS was the rate of SDAI remission at 52 weeks after initiation of abatacept therapy. The secondary endpoints included that of Saxson's test and Schirmer's test. Adverse events during the study period were also analyzed. Results. Thirty-two patients (all females) were enrolled in this study. Interim analysis at 24 weeks included assessment of efficacy (n = 31) and safety (n = 32). The mean SDAI decreased from 19.8 ± 11.0 (± SD) at baseline to 9.9 ± 9.9 at 24 weeks (P < 0.05). Patients with clinical remission, as assessed by SDAI, increased from 0 patient (0 week) to 8 patients (25.8%) at 24 weeks. Saliva volume (assessed by Saxson's test) increased slightly from 2232 ± 1908 (0 week) to 2424 ± 2004 (24 weeks) mg/2 min (n = 29). In 11 patients with Greenspan grading 1/2 of labial salivary glands biopsy, saliva volume increased from 2945 ± 2090 (0 week) to 3419 ± 2121 (24 weeks) mg/2 min (P < 0.05). Schirmer's test for tear volume showed increase from 3.6 ± 4.6 (0 week) to 5.5 ± 7.1 (24 weeks) mm/5 min (n = 25; P < 0.05). Five adverse events occurred in five of 32 patients (15.6%), and three of these events were infections. Conclusion. Abatacept seems to be effective for both RA and RA-related secondary SS.

Keywords: Abatacept; Rheumatoid arthritis; Sjögren's syndrome.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effect of abatacept on RA. (A) Effects of abatacept treatment on Simplified Disease Activity Index (SDAI) in 31 patients. Data deficit was compensated by the last observation carried forward (LOCF) method (∗P < 0.05 vs. 0 week [baseline]), Wilcoxon signed-rank test. ABT, abatacept. (B) Effects of abatacept treatment on SDAI in 7 bio-switch patients and 24 bio-naïve patients. Data deficit compensated by the LOCF method (∗P < 0.05 vs. 0 week [baseline]), Wilcoxon signed-rank test. The difference between two groups was examined using Mann–Whitney U-test. ABT, abatacept; N.S, not significant. (C) Effects of abatacept and methotrexate combination treatment on SDAI in 23 patients and of abatacept alone in 8 patients. Data deficit was compensated by the LOCF method (∗P < 0.05 vs 0 week [baseline]), Wilcoxon signed-rank test. Difference between two groups was examined using Mann–Whitney U test. ABT, abatacept; N.S, not significant.
Figure 2.
Figure 2.
Effect of abatacept treatment on RA disease activity. Effects of abatacept treatment on disease activity as assessed by SADI in 31 patients. Data deficit was compensated by the LOCF method. ABT, abatacept.
Figure 3.
Figure 3.
Effect of abatacept on VAS in SS. (A) Effects of abatacept treatment on patients' VAS for dry mouth, dry eye, and parotid pain in 29 patients. Data deficit was compensated by the LOCF method (∗P < 0.05 vs 0 week [baseline]), Wilcoxon signed-rank test. VAS, visual analog scale; N.S, not significant. (B) Effects of abatacept treatment on physicians' VAS for dry mouth, keratoconjunctivitis sicca, and general condition in 28 patients. Data deficit was compensated by the LOCF method (∗P < 0.05 vs 0 week [baseline]), Wilcoxon signed-rank test. VAS, visual analog scale; KCS, keratoconjunctivitis sicca.
Figure 4.
Figure 4.
Effects of abatacept on secretory function in SS. (A) Effects of abatacept treatment on saliva volume assessed by Saxson's test in 29 patients. Data deficit was compensated by the LOCF method. N.S, not significant vs. 0 week (baseline); Wilcoxon signed-rank test; ABT, abatacept. (B) Effect of abatacept treatment on saliva volume assessed by Saxson's test in 11 patients with Greenspan grading 1/2 of labial salivary gland (LSG) biopsy and in 16 patients with grade 3/4. Data deficit was compensated by the LOCF method (∗P < 0.05 vs 0 week [baseline]), Wilcoxon signed-rank test. Difference between two groups was examined using Mann–Whitney U test. ABT, abatacept; N.S, not significant. (C) Effects of abatacept treatment on tear volume assessed by Schirmer's test in 25 patients. Data deficit was compensated by the LOCF method (∗P < 0.05 vs. 0 week [baseline]), Wilcoxon signed-rank test. ABT, abatacept.
Figure 5.
Figure 5.
Effect of abatacept on IgG, RF, and anti-SS-A antibody in SS. Effects of abatacept treatment on (A) serum IgG level (n = 31), (B) serum RF level (n = 30 patients), (C) titer of anti-SS-A antibody (n = 20 patients). Data deficit was compensated by the LOCF method (∗P < 0.05 vs 0 week [baseline]), N.S; not significant vs baseline, Wilcoxon signed-rank test. ABT; abatacept.
Figure 6.
Figure 6.
Correlation between improvement in SS and RA. Correlation between (A) increase in saliva volume (assessed by Saxon's test) and fall in SDAI (n = 29 patients). Spearman's rank correlation coefficient = 0.211, not significant, and (B) between increase of tear volume (assessed by Schirmer's test) and fall in SDAI (n = 25 patients). Data deficit was compensated by the LOCF method. Spearman's rank correlation coefficient = 0.333, not significant.
See this image and copyright information in PMC

References

    1. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8. - PMC - PubMed
    1. Tsuboi H, Asashima H, Takai C, Hagiwara S, Hagiya C, Yokosawa M, et al. Primary and secondary surveys on epidemiology of Sjogren's syndrome in Japan. Mod Rheumatol. 2014;24(3):464–70. - PubMed
    1. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol. 2012;8(7):399–411. - PubMed
    1. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960–8. - PubMed
    1. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–4. - PubMed

Publication types